| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/28/2010 | US7803758 I kappa B kinase complex as a target for the treatment of Huntington's disease |
| 09/28/2010 | US7803757 For treatment of urinary tract infections and inflammations, colitis, and candida infections of mucosal membranes; infant formula food containing the peptide |
| 09/28/2010 | US7803756 Systemic or local administration of a lipopolysaccharide binding polypeptide; neutralizes microbial toxins and allows natural host defence mechanisms to control spread of infection; otitis media; antibiotic resistance |
| 09/28/2010 | US7803755 Molecules for the treatment and prevention of fungal diseases |
| 09/28/2010 | US7803754 Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
| 09/28/2010 | US7803753 combination of GPR119 agonist with a dipeptidyl peptidase IV (DPP-IV) inhibitor such that combination provides effect in lowering a blood glucose level or in increasing blood GLP-1 level over that provided by GPR119 agonist or DPP-IV inhibitor alone; for treating or preventing diabetes; synergistic |
| 09/28/2010 | US7803752 Method of inducing neuronal production in the caudate nucleus and putamen |
| 09/28/2010 | US7803750 Using zinc glycoprotein |
| 09/28/2010 | US7803749 Prevent signal transduction passageways; kinase inhibitor; modulate immunology response |
| 09/28/2010 | US7803748 Nanoparticles for protein drug delivery |
| 09/28/2010 | US7803618 nucleic acid encoding an anti-EpCAM protein; binds human epithelial cell adhesion molecule; immunoglobulin light chain region modified to reduce immunogenicity; diagnosis, prognosis and treatment of cancer |
| 09/28/2010 | US7803615 Death domain containing receptor 5 |
| 09/28/2010 | US7803614 isolated host cell transfected with the recombinant expression vector encoding an immunogenic protein; diagnosis of skin cancer; vaccine for prevent and treatment; immunotherapy |
| 09/28/2010 | US7803613 Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
| 09/28/2010 | US7803602 Method for overexpression of zwitterionic polysaccharides |
| 09/28/2010 | US7803595 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof |
| 09/28/2010 | US7803577 Polynucleotide encoding a tropoelastin polypeptide; expression products and hybrid molecules of the derivatives and variants |
| 09/28/2010 | US7803576 Nucleic acid sequences encoding VEGF-like factors and uses thereof |
| 09/28/2010 | US7803571 Using insulin receptor substrate peptides as diagnostic tool in identifying modulators of protein kinase activity; enzyme inhibitor; mimetics |
| 09/28/2010 | US7803562 Method for screening human intestinal Npt2B modulatory agents |
| 09/28/2010 | US7803560 Contacting a candidate antagonist with a MCP-1 receptor polypeptide having an amino acid sequence at least 95% homologous to an extracellular domain of a specific sequence, and comparing the binding of MCP-1 to the receptor polypeptide; decreased binding indicates an antagonist |
| 09/28/2010 | US7803558 Screening for a substance that inhibits VE-cadherin protein adhesion between Schlemm's canal cells by culturing the cells on a plate containing of all of the extracellular domain of VE-cadherin in the presence of the substance and measuring adhesion; reduced adhesion indicates a good candidate |
| 09/28/2010 | US7803555 Determining the effect of a test compound on the binding interaction between a folate receptor and a folate receptor-binding fragment of a filovirus envelope glycoprotein; a compound that reduces binding is a candidate compound for slowing the progression of a filovirus, e.g., Ebola, mediated disease |
| 09/28/2010 | US7803531 Anticancer, antitumor agents |
| 09/28/2010 | US7803408 Use of human erythropoietin (EPO) to prevent or treat endothelial injury due to chemotherapy, radiation therapy, mechanical trauma, or to a disease state which damages the endothelium |
| 09/28/2010 | US7803404 Promoting binding of a drug, to a crystalline microparticle of a diketopiperazine in suspension by modifying the chemical potential of the drug to allow for an energetically favorable interaction between the two independent; adsorbing, coating drug on the microparticle surface; drug delivery |
| 09/28/2010 | US7803400 Comprised of three lipid elements: phosphatidyl choline, fatty-acyl-cholesterol esters, and at least one apolipoprotein; brain disorders; kits; efficiently target and deliver substances |
| 09/28/2010 | US7803399 Delivery system for nucleic acids |
| 09/28/2010 | US7803391 Bacillus thuringiensis; conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds; controlling beetles; vectors, host cells |
| 09/28/2010 | US7803388 Polymorphic membrane proteins or PMPs of Chlamydia, amino acid and nucleotide sequences; immunogens; vaccines; biodrugs;respiratory system disorders; urogenital system disorders; genetic engineering |
| 09/28/2010 | US7803387 With proteins of nisseria and purification of domains and gene expression of oligopeptides of ser, lys, ala, glu, gly and met |
| 09/28/2010 | US7803386 An immunogenic conjugate comprising a synthetic homopolymer of poly- gamma -glutamic acidpolypeptide covalently linked to a carrier, where the conjugate elicits an immune response against poly- gamma -glutamic acid ( gamma PGA) polypeptide; vaccine with fewer dosages; anthrax; diptheria |
| 09/28/2010 | US7803383 Method of treatment comprising administration of a cytokine antagonist molecule |
| 09/28/2010 | US7803381 Synthetic peptide comprising the amino acid sequence GPRLGYSWHX in which each of the amino acids are in the D-amino acid configuration and X is any amino acid; optionally conjugated to the natural gonadotropin-releasing hormone peptide; vaccines for use incontrolling fertility or heat in an animal |
| 09/28/2010 | US7803380 Reducing the growth of an osteopontin-expressing tumor cell, such as metastatic hepatocellular carcinoma, by administering a peptide that reduces cellular invasion resulting from the interaction between a fragment of OPN generated by metalloproteinase-9 cleavage and CD44 receptor; diagnosis by OPN level |
| 09/28/2010 | US7803379 Tumour-specific animal proteins |
| 09/28/2010 | US7803375 Reducing leakage from unwanted choroidal neovasculature by administering an anti-FasL factor to permit an effective amount to localize in the neovasculature, administering a photosensitizer to the neovasculature, and irradiating it with laser light; photodynamic therapy |
| 09/28/2010 | US7803374 Targeted atherosclerosis treatment |
| 09/28/2010 | US7803373 Chemokine panec-1 antibodies |
| 09/28/2010 | US7803369 Devices and method for repair of larynx, trachea, and other fibrocartilaginous tissues |
| 09/28/2010 | US7803368 Liquefying a vitreous and/or inducing posterior vitreous detachment of an eye via microplasmin injection; treating vision defects; preventing or reducing the risk of retinal detachment |
| 09/28/2010 | US7803366 Methods and compositions that enhance bioavailability of coenzyme-Q10 |
| 09/28/2010 | US7803362 Glycosylated with galactose-N-acetylgalactosamine; used for the introduction of exogenous nucleic acid sequences into the genome of avians in order to express the exogenous sequences to alter the phenotype of the avians or to produce desired proteins |
| 09/28/2010 | US7803361 Decreasing solid tumor size in a cancer patient by administering an interleukin-2 mutant with reduced vasopermeability activity compared to a wildtype form, and being Arg38Trp, wherein said wildtype form is human IL-2 mutant and the IL-2 mutant is not linked to an antibody. |
| 09/28/2010 | CA2474430C A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction |
| 09/28/2010 | CA2449952C Medicinal composition |
| 09/28/2010 | CA2430366C Improved oral delivery of peptides using enzyme-cleavable membrane translocators |
| 09/28/2010 | CA2376260C High density lipoprotein against organ dysfunction following haemorrhagic shock |
| 09/28/2010 | CA2323503C Novel physiological active peptide and its use |
| 09/28/2010 | CA2286288C Monoclonal antibody recognizing the n-glycolylated-galacotose-glucose sialic acid oligosaccharide in malignant tumors and composition that contains it |
| 09/28/2010 | CA2285746C Osteoprotegerin binding proteins and receptors |
| 09/28/2010 | CA2268525C The use of growth hormone as an aid for hypothermia |
| 09/28/2010 | CA2238050C Inhibitors of cyclophilin rotamase activity |
| 09/28/2010 | CA2235866C Methods of treating established colitis using antibodies against il-12 |
| 09/28/2010 | CA2188017C Cardiotrophin and uses therefor |
| 09/28/2010 | CA2153494C Novel parasitic helminth proteins |
| 09/23/2010 | WO2010108177A2 A method and composition using a dual specificity protein tyrosine phosphatase as an antimalarial drug target |
| 09/23/2010 | WO2010108172A1 Crystalline tripeptide epoxy ketone protease inhibitors |
| 09/23/2010 | WO2010108164A2 Novel anti-parasitic compounds |
| 09/23/2010 | WO2010108154A2 Selective and potent peptide inhibitors of kv1.3 |
| 09/23/2010 | WO2010108122A1 Targeted delivery of chemotherapeutic agents |
| 09/23/2010 | WO2010108114A2 Polyunsaturated fatty acid synthase nucleic acid molecules and polypeptides, compositions, and methods of making and uses thereof |
| 09/23/2010 | WO2010108028A2 Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same |
| 09/23/2010 | WO2010108001A2 Agents and methods for tissue repair and regeneration |
| 09/23/2010 | WO2010107909A2 Methods and compositions for the detection of cancer |
| 09/23/2010 | WO2010107874A2 Methods for affecting body composition using amylin agonists |
| 09/23/2010 | WO2010107832A1 Lhrh-ii peptide analogs |
| 09/23/2010 | WO2010107825A2 Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities |
| 09/23/2010 | WO2010107658A2 Methods and compositions for bi-specific targeting of cd19/cd22 |
| 09/23/2010 | WO2010107520A1 Soluble non-depot insulin conjugates and uses thereof |
| 09/23/2010 | WO2010107519A1 Terminally-functionalized conjugates and uses thereof |
| 09/23/2010 | WO2010107486A2 Use of somatostatin or an analogue thereof in combination with external radiation therapy |
| 09/23/2010 | WO2010107414A1 Enzyme compositions and use thereof |
| 09/23/2010 | WO2010107116A1 Hla-a24-binding cancer antigen peptide derived from sox2 |
| 09/23/2010 | WO2010106812A1 Pharmaceutical formulation containing improved antibody molecules |
| 09/23/2010 | WO2010106542A2 USE OF NKp46 FOR PREVENTING DIABETES |
| 09/23/2010 | WO2010106509A2 Hcv-derived polypeptides and uses thereof |
| 09/23/2010 | WO2010106441A2 Peptidomimetics for modulating interleukin-1 receptor |
| 09/23/2010 | WO2010106437A1 Peptides that inhibit angiotensin converting enzyme and peptides with antioxidant activity purified from ovotransferrin and methods of producing and using the same |
| 09/23/2010 | WO2010106295A1 Use of decorin for increasing muscle mass |
| 09/23/2010 | WO2010106294A1 Peptides modulating the activity of igf-1 and the applications of said peptides |
| 09/23/2010 | WO2010106187A2 Inhibitors of cathepsin s for prevention or treatment of obesity-associated disorders |
| 09/23/2010 | WO2010105856A1 Methods and compositions for modulating cardiac contractility |
| 09/23/2010 | WO2010105685A1 Peptides for inhibiting igf-1 |
| 09/23/2010 | WO2010105636A1 Topical compositions comprising interleukin-1 alpha and peptides and cosmetic methods thereof |
| 09/23/2010 | WO2010105573A1 Anti-angiogenic fusion proteins |
| 09/23/2010 | WO2010105491A1 Preparation method of oxalate-degrading enzymes included in plant fiber or insoluble ingredient of microoganisms and use thereof |
| 09/23/2010 | WO2010105450A1 A layered double hydroxide complex inserted by carnosine and the preparation method thereof |
| 09/23/2010 | WO2010105302A1 Targets for growth factor signalling and methods of therapy |
| 09/23/2010 | WO2010088502A3 Insulin-like growth factor signaling and integrin |
| 09/23/2010 | WO2010086512A3 Lactobacillus rhamnosus pilus polypeptides and methods for producing them |
| 09/23/2010 | WO2010085700A3 Treatment for obesity |
| 09/23/2010 | WO2010083051A3 Cartilage particle tissue mixtures optionally combined with a cancellous construct |
| 09/23/2010 | WO2010081622A3 Food supplement for the treatment of neuropathies |
| 09/23/2010 | WO2010065735A3 Methods and compositions for treating p.acnes |
| 09/23/2010 | WO2010065563A3 Apratoxin therapeutic agents: mechanism and methods of treatment |
| 09/23/2010 | WO2010062863A3 Compositions containing satiogens and methods of use |
| 09/23/2010 | WO2010040147A3 Site-specific n-terminal modifications of proteins and conjugate formation |
| 09/23/2010 | WO2010033617A3 Stapled peptides and method of synthesis |
| 09/23/2010 | WO2010033425A3 Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment |